Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the stock.

Bio-Path Stock Down 10.4%

Shares of Bio-Path stock opened at $0.17 on Wednesday. The company has a fifty day moving average of $0.16 and a 200 day moving average of $0.53. Bio-Path has a fifty-two week low of $0.12 and a fifty-two week high of $4.55.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.